Erectile Dysfunction Pipeline Review, H2 2020 -

DUBLIN--()--The "Erectile Dysfunction - Pipeline Review, H2 2020" drug pipelines has been added to's offering.

The latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Erectile Dysfunction pipeline landscape.

The pipeline guide provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 3, 6, 5, 14, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Scope of the report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction.
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Key Topics Covered:

  • Erectile Dysfunction - Overview
  • Erectile Dysfunction - Therapeutics Development
  • Erectile Dysfunction - Therapeutics Assessment
  • Erectile Dysfunction - Companies Involved in Therapeutics Development
  • Erectile Dysfunction - Drug Profiles
  • Erectile Dysfunction - Dormant Projects
  • Erectile Dysfunction - Discontinued Products
  • Erectile Dysfunction - Product Development Milestones

Companies Mentioned

  • AnyGen Co Ltd
  • Aprogen Inc
  • Aquestive Therapeutics Inc
  • Astellas Pharma Inc
  • Biozeus Pharmaceutical SA
  • Can-Fite BioPharma Ltd
  • CardioVascular BioTherapeutics Inc
  • Cure Pharmaceutical Inc
  • Dicot AB
  • Druggability Technologies Holdings Ltd
  • Exopharm Ltd
  • Fabre-Kramer Pharmaceuticals Inc
  • Futura Medical Plc
  • Guangzhou Four-Leaf Clover HealthTech Co Ltd
  • Hemostemix Inc
  • Humanetics Corp
  • ILGEN Inc
  • Initiator Pharma AS
  • IntelGenx Corp
  • Klaria Pharma Holding AB
  • Mezzion Pharma Co Ltd
  • MicroCures Inc
  • Mitsubishi Tanabe Pharma Corp
  • MyX Therapeutics Inc
  • NAL Pharmaceuticals Ltd
  • Organicell Regenerative Medicine Inc
  • Pharmicell Co Ltd
  • Reven Pharmaceuticals Inc
  • Seelos Therapeutics, Inc.
  • siRNAgen Therapeutics Corp
  • Suda Pharmaceuticals Ltd
  • Targazyme Inc
  • Techfields Pharma Co Ltd
  • Tritech Biopharmaceuticals Co Ltd
  • Veru Inc
  • XuanZhu Pharma Co Ltd
  • Yangtze River Pharmaceutical Group

For more information about this drug pipelines report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900